Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer

L. Repetto, L. Miglietta, G. Gardin, C. Naso, S. Giudici, L. Merlini, P. Queirolo, E. Campora, P. Pronzato, R. Rosso

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.

Original languageEnglish
Pages (from-to)165-166
Number of pages2
JournalAnnals of Oncology
Volume3
Issue number2
Publication statusPublished - 1992

Fingerprint

Mitoxantrone
Mitomycin
Breast Neoplasms
Disease-Free Survival
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Repetto, L., Miglietta, L., Gardin, G., Naso, C., Giudici, S., Merlini, L., ... Rosso, R. (1992). Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. Annals of Oncology, 3(2), 165-166.

Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. / Repetto, L.; Miglietta, L.; Gardin, G.; Naso, C.; Giudici, S.; Merlini, L.; Queirolo, P.; Campora, E.; Pronzato, P.; Rosso, R.

In: Annals of Oncology, Vol. 3, No. 2, 1992, p. 165-166.

Research output: Contribution to journalArticle

Repetto, L, Miglietta, L, Gardin, G, Naso, C, Giudici, S, Merlini, L, Queirolo, P, Campora, E, Pronzato, P & Rosso, R 1992, 'Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer', Annals of Oncology, vol. 3, no. 2, pp. 165-166.
Repetto L, Miglietta L, Gardin G, Naso C, Giudici S, Merlini L et al. Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. Annals of Oncology. 1992;3(2):165-166.
Repetto, L. ; Miglietta, L. ; Gardin, G. ; Naso, C. ; Giudici, S. ; Merlini, L. ; Queirolo, P. ; Campora, E. ; Pronzato, P. ; Rosso, R. / Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. In: Annals of Oncology. 1992 ; Vol. 3, No. 2. pp. 165-166.
@article{d11b9ba2c9e3464c952c6a4a218ded58,
title = "Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer",
abstract = "Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4{\%}) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.",
author = "L. Repetto and L. Miglietta and G. Gardin and C. Naso and S. Giudici and L. Merlini and P. Queirolo and E. Campora and P. Pronzato and R. Rosso",
year = "1992",
language = "English",
volume = "3",
pages = "165--166",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer

AU - Repetto, L.

AU - Miglietta, L.

AU - Gardin, G.

AU - Naso, C.

AU - Giudici, S.

AU - Merlini, L.

AU - Queirolo, P.

AU - Campora, E.

AU - Pronzato, P.

AU - Rosso, R.

PY - 1992

Y1 - 1992

N2 - Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.

AB - Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026584074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026584074&partnerID=8YFLogxK

M3 - Article

C2 - 1606088

AN - SCOPUS:0026584074

VL - 3

SP - 165

EP - 166

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -